Bristol Myers Squibb (BMS) is stepping up its game in drug discovery by weaving artificial intelligence (AI) and machine learning into its deep expertise in drug targets and mechanisms of action. This exciting initiative, called “Predict First,” is all about boosting the way they dream up, design, and assess promising molecules in their vast pipeline.
Greg Meyers, BMS’ executive vice president and chief digital & technology officer, shares an interesting perspective. He likens the current state of AI in the pharmaceutical world to the early days of personal computing back in the 1980s. Meyers is confident that these technological leaps are set to reshape everything—from how we develop medicines to enhancing patient experiences and even transforming core business operations.
BMS has been in the AI game even before the COVID-19 pandemic hit. Back in 2019, they teamed up with Concert HealthAI to speed up clinical trials and improve precision treatment. That same year, BMS acquired Celgene, which strengthened their collaboration with AI trailblazer Exscientia.
Robert Plenge, BMS’ executive vice president and chief research officer, highlights how AI tools are changing the research landscape at BMS. These technologies offer deeper insights into human biology and enable more effective data usage, which is having a significant impact on their research strategy.
In collaboration with various tech-savvy partners like VantAI, BMS is using generative AI to craft molecular glues for small-molecule therapeutics. With a hefty $674 million agreement in place, BMS is set on hitting discovery and development milestones.
AI isn’t just revolutionizing research; it’s also optimizing BMS’ manufacturing processes and expanding their chemical libraries. By predicting and diversifying chemical space, AI has boosted the success rates of finding viable molecules for targeted protein degradation.
Meyers states that AI and machine learning are everywhere within BMS, from research and development to managing accounts and contracts. The integration of AI tools aims to enhance productivity and efficiency, freeing up employees to focus on more impactful tasks.
BMS is committed to its AI partnerships, viewing the broader biopharma landscape as a collaborative ecosystem where both large and specialized companies can thrive. As AI continues to evolve, BMS is eager to leverage these technologies to bring innovative medicines to patients more quickly.
